Join
Live feed
·
NEWSReleasevia Quantisnow
Quince Therapeutics Inc. logo

Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026

ByQuantisnow·Wall Street's wire, on your screen.
QNCX· Quince Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QNCX (Quince Therapeutics Inc.) and more on Quantisnow.